TY - JOUR
T1 - Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients
AU - McNaghten, A. D.
AU - Hanson, Debra L.
AU - Dworkin, Mark S.
AU - Jones, Jeffrey L.
AU - Turner, Jane
AU - Wohl, Amy
AU - Cohn, David
AU - Davidson, Arthur
AU - Rietmeijer, Cornelius
AU - Gable, Julia
AU - Thompson, Melanie
AU - Broyles, Stephanie
AU - Morse, Anne
AU - Mokotoff, Eve
AU - Wotring, Linda
AU - Sackoff, Judy
AU - De los Angeles Gomez, Maria
AU - Hunter, Robert
AU - Otero, Jose
AU - Miranda, Sandra
AU - Melville, Sharon
AU - Odem, Sylvia
AU - Keiser, Philip
AU - McNeely, Wes
AU - Reynolds, Kaye
AU - Buskin, Susan
AU - Hopkins, Sharon
PY - 2003/4/15
Y1 - 2003/4/15
N2 - The objective of this study was to determine factors associated with prescription of highly active antiretroviral therapy (HAART). The authors observed 9530 patients eligible for antiretroviral therapy (ART) in more than 100 hospitals and clinics in 10 US cities. Multiple logistic regression analysis was used to assess factors associated with HAART prescription, stratifying patients by no history versus history of ART to assess the association between prescription and CD4, viral load, and outpatient visits. Overall, female gender (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.60-0.76) and alcoholism (OR, 0.85; 95% CI, 0.74-0.99) were associated with decreased likelihood of HAART prescription. Enrollment at a private facility (OR, 1.33; 95% CI, 1.14-1.56), heterosexual exposure (OR, 1.34; 95% CI, 1.13-1.58), and Hispanic ethnicity (OR, 1.19; 95% CI, 1.04-1.37) were associated with prescription. For patients with no history of prescribed ART, CD4 <500 cells/μL (OR, 3.94; 95% CI, 2.02-7.66), and high viral load were associated with increased likelihood of prescription; for patients with history of ART prescription, those whose outpatient visits averaged ≥2 per 6-month interval (OR, 1.30; 95% CI, 1.10-1.54) were more likely and those with high viral load were less likely to be prescribed HAART (OR, 0.50; 95% CI, 0.44-0.56). The authors found differences in HAART prescription by gender, race, exposure mode, alcoholism, and provider type for all patients, by CD4 and viral load for patients with no history of ART prescription, and by average number of outpatient visits and viral load for patients with history of ART prescription.
AB - The objective of this study was to determine factors associated with prescription of highly active antiretroviral therapy (HAART). The authors observed 9530 patients eligible for antiretroviral therapy (ART) in more than 100 hospitals and clinics in 10 US cities. Multiple logistic regression analysis was used to assess factors associated with HAART prescription, stratifying patients by no history versus history of ART to assess the association between prescription and CD4, viral load, and outpatient visits. Overall, female gender (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.60-0.76) and alcoholism (OR, 0.85; 95% CI, 0.74-0.99) were associated with decreased likelihood of HAART prescription. Enrollment at a private facility (OR, 1.33; 95% CI, 1.14-1.56), heterosexual exposure (OR, 1.34; 95% CI, 1.13-1.58), and Hispanic ethnicity (OR, 1.19; 95% CI, 1.04-1.37) were associated with prescription. For patients with no history of prescribed ART, CD4 <500 cells/μL (OR, 3.94; 95% CI, 2.02-7.66), and high viral load were associated with increased likelihood of prescription; for patients with history of ART prescription, those whose outpatient visits averaged ≥2 per 6-month interval (OR, 1.30; 95% CI, 1.10-1.54) were more likely and those with high viral load were less likely to be prescribed HAART (OR, 0.50; 95% CI, 0.44-0.56). The authors found differences in HAART prescription by gender, race, exposure mode, alcoholism, and provider type for all patients, by CD4 and viral load for patients with no history of ART prescription, and by average number of outpatient visits and viral load for patients with history of ART prescription.
KW - Antiretroviral therapy
KW - HAART prescription
KW - Highly active antiretroviral therapy (HAART)
UR - http://www.scopus.com/inward/record.url?scp=0037446439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037446439&partnerID=8YFLogxK
U2 - 10.1097/00126334-200304150-00006
DO - 10.1097/00126334-200304150-00006
M3 - Article
C2 - 12679701
AN - SCOPUS:0037446439
SN - 1525-4135
VL - 32
SP - 499
EP - 505
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 5
ER -